Eric Santos, MD
Hematology & Oncology · Grand Rapids, MINPI 1174700256
Payments from drug & device makers
Across 187 payments — averaging $8159.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$868K
- AstraZeneca$262K
- Genentech, Inc.$151K
- Eli Lilly$114K
- Sanofi US Services Inc.$90K
- Merck$33K
- plus $7K from 29 others
Across 3 payments — averaging $825.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $868,366 |
| AstraZeneca | 27 | $261,705 |
| Genentech, Inc. | 23 | $150,813 |
| Eli Lilly | 3 | $114,362 |
| Sanofi US Services Inc. | 22 | $90,056 |
| Merck | 7 | $33,340 |
| Sanofi | 4 | $3,211 |
| Astrazeneca UK Limited | 9 | $1,559 |
| Foundation Medicine, Inc. | 3 | $470 |
| E.r. Squibb & Sons, L.L.C. | 10 | $463 |
| Array Biopharma Inc | 12 | $238 |
| Novartis | 13 | $217 |
| Gilead(2 entities) | 4 | $168 |
| Regeneron Healthcare Solutions, Inc. | 3 | $116 |
| Genentech USA, Inc. | 6 | $108 |
| Catalyst Orthoscience | 1 | $104 |
| Pfizer | 6 | $83 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $64 |
| Eisai Inc. | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Bristol Myers Squibb | 2 | $32 |
| GSK | 2 | $32 |
| Bayer | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Seagen Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| AbbVie | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
How this compares
$1,525,851 in reported general payments places this provider in the 90th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Brett BrinkerGrand Rapids$2.3M
- Andrew SochackiGrand Rapids$1.4M
- Amy Vander WoudeGrand Rapids$1.2M
- Colin HardinGrand Rapids$974K
- Erin PettijohnGrand Rapids$871K
- Latha PolavaramGrand Rapids$69K
- Timothy OrourkeGrand Rapids$55K
- Hirva MamdaniDetroit$9.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.